NRG-GY019
Closed to Accrual
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Status
Closed to Accrual
Open to Accrual
August 26, 2019
Closed to Accrual
May 9, 2025
Disease Site
Gynecologic [GY] Ovarian
Phase
III
Developmental Therapeutics
No
Primary Objective
To examine if letrozole monotherapy/maintenance is non-inferior to IV paclitaxel/carboplatin and maintenance letrozole with respect to PFS in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction.
Patient Population
Women with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum after primary surgical cytoreduction.
Target Accrual
450
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
